These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30198876)

  • 21. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin-Deficient D2.B10-Dmd
    Hayes HM; Angerosa J; Piers AT; White JD; Koleff J; Thurgood M; Moody J; Cheung MM; Pepe S
    Oxid Med Cell Longev; 2022; 2022():5362115. PubMed ID: 35340200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment.
    Butchart LC; Terrill JR; Rossetti G; White R; Filipovska A; Grounds MD
    Int J Biochem Cell Biol; 2018 Jun; 99():52-63. PubMed ID: 29578051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy.
    Terrill JR; Grounds MD; Arthur PG
    Int J Biochem Cell Biol; 2015 Sep; 66():141-8. PubMed ID: 26239309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-invasive MRI and spectroscopy of mdx mice reveal temporal changes in dystrophic muscle imaging and in energy deficits.
    Heier CR; Guerron AD; Korotcov A; Lin S; Gordish-Dressman H; Fricke S; Sze RW; Hoffman EP; Wang P; Nagaraju K
    PLoS One; 2014; 9(11):e112477. PubMed ID: 25390038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene.
    Licandro SA; Crippa L; Pomarico R; Perego R; Fossati G; Leoni F; Steinkühler C
    Skelet Muscle; 2021 Jul; 11(1):19. PubMed ID: 34294164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Murine models of Duchenne muscular dystrophy: is there a best model?
    Swiderski K; Lynch GS
    Am J Physiol Cell Physiol; 2021 Aug; 321(2):C409-C412. PubMed ID: 34260298
    [No Abstract]   [Full Text] [Related]  

  • 27. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
    Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
    Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.
    Ponnusamy S; Sullivan RD; You D; Zafar N; He Yang C; Thiyagarajan T; Johnson DL; Barrett ML; Koehler NJ; Star M; Stephenson EJ; Bridges D; Cormier SA; Pfeffer LM; Narayanan R
    Hum Mol Genet; 2017 Jul; 26(13):2526-2540. PubMed ID: 28453658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
    Ito M; Ehara Y; Li J; Inada K; Ohno K
    Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
    Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoid Receptor Antagonists in Muscular Dystrophy Mice During Aging and Exercise.
    Lowe J; Kadakia FK; Zins JG; Haupt M; Peczkowski KK; Rastogi N; Floyd KT; Gomez-Sanchez EP; Gomez-Sanchez CE; Elnakish MT; Rafael-Fortney JA; Janssen PML
    J Neuromuscul Dis; 2018; 5(3):295-306. PubMed ID: 30010143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of qPCR Reference Genes Suitable for Normalizing Gene Expression in a Canine Model of Duchenne Muscular Dystrophy.
    Hildyard JCW; Taylor-Brown F; Massey C; Wells DJ; Piercy RJ
    J Neuromuscul Dis; 2018; 5(2):177-191. PubMed ID: 29614692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro mouse model in Duchenne muscular dystrophy diagnosis using 50-MHz ultrasound waves.
    Laux D; Blasco H; Ferrandis JY; Hugon G; Despaux G; Leydier A; Mornet D
    Ultrasonics; 2010 Aug; 50(8):741-3. PubMed ID: 20462623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
    Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
    Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
    Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
    BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.
    Collins CA; Morgan JE
    Int J Exp Pathol; 2003 Aug; 84(4):165-72. PubMed ID: 14632630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensorimotor control of breathing in the mdx mouse model of Duchenne muscular dystrophy.
    Burns DP; Roy A; Lucking EF; McDonald FB; Gray S; Wilson RJ; Edge D; O'Halloran KD
    J Physiol; 2017 Nov; 595(21):6653-6672. PubMed ID: 28952155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and localization of protein inhibitor of neuronal nitric oxide synthase in Duchenne muscular dystrophy.
    Guo Y; Petrof BJ; Hussain SN
    Muscle Nerve; 2001 Nov; 24(11):1468-75. PubMed ID: 11745948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
    Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
    Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.